Literature DB >> 26887451

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Anastasia S Proskurina1, Tatiana S Gvozdeva2, Ekaterina A Alyamkina3, Evgenia V Dolgova4, Konstantin E Orishchenko5, Valeriy P Nikolin6, Nelly A Popova7,8, Sergey V Sidorov9,10, Elena R Chernykh11, Alexandr A Ostanin12, Olga Y Leplina13, Victoria V Dvornichenko14,15, Dmitriy M Ponomarenko16,17, Galina S Soldatova18,19, Nikolay A Varaksin20, Tatiana G Ryabicheva21, Peter N Uchakin22, Stanislav N Zagrebelniy23, Vladimir A Rogachev24, Sergey S Bogachev25, Mikhail A Shurdov26.   

Abstract

Entities:  

Year:  2016        PMID: 26887451      PMCID: PMC4757989          DOI: 10.1186/s12885-016-2163-y

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


× No keyword cloud information.

Erratum

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In this erratum we rectify these mistakes. The full list of authors and the updated Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused. Corrected Authors’ List: Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Alyamkina, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin, Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S. Bogachev, and Mikhail A. Shurdov.
  1 in total

1.  Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Authors:  Anastasia S Proskurina; Tatiana S Gvozdeva; Ekaterina A Alyamkina; Evgenia V Dolgova; Konstantin E Orishchenko; Valeriy P Nikolin; Nelly A Popova; Sergey V Sidorov; Elena R Chernykh; Alexandr A Ostanin; Olga Y Leplina; Victoria V Dvornichenko; Dmitriy M Ponomarenko; Galina S Soldatova; Nikolay A Varaksin; Tatiana G Ryabicheva; Peter N Uchakin; Stanislav N Zagrebelniy; Vladimir A Rogachev; Sergey S Bogachev; Mikhail A Shurdov
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.